Pravin T Kaumaya, PhD

College

College of Medicine

Department/Division

Obstetrics & Gynecology

Academic Title

Professor

Research Program

Translational Therapeutics

Research Interest

Cancer, Mammary Cancer, Experimental, Breast Cancer, Encephalomyelitis, Autoimmune, Experimental, Lung Cancer, Disease Models, Animal, Neovascularization, Pathologic, Cancer, Experimental, Infection, HTLV-I Infections

Dr. Kaumaya investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells

Education and Background

Office Location

316 Tzagournis Med Res Facility

420 W 12th Avenue, Columbus, Ohio 43210

614-292-7028

614-292-1135

kaumaya.1@osu.edu

Publications

Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B

Onco Targets Ther 9 2769-81 01/01/2016
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT

Vaccines (Basel) 3 519-43 07/06/2015
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Kaumaya PT

Hum Vaccin Immunother 11 1368-86 01/01/2015
Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.

Kaumaya PT

Immunotherapy 5 1159-63 11/01/2013
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Overholser JP, Bekaii-Saab T, Kaumaya PT, Foy KC, Wygle RM, Miller MJ

J Immunol 191 217-27 07/01/2013
Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.

Miller MJ, Foy KC, Kaumaya PT

Discov Med 15 166-76 03/01/2013
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.

Foy KC, Miller MJ, Moldovan N, Carson WE 3rd, Kaumaya PT, Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PT

Oncoimmunology 1 1048-1060 10/01/2012
Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.

Foy KC, Miller MJ, Moldovan N, Carson WE 3rd, Kaumaya PT, Foy KC, Miller MJ, Moldovan N, Carson Iii WE, Kaumaya PT

Oncoimmunology 1 1048-1060 10/01/2012
Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PT, Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT

Oncoimmunology 1 1004-1016 10/01/2012
Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson Iii WE, Kaumaya PT, Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT

Oncoimmunology 1 1004-1016 10/01/2012
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Kaumaya PT, Foy KC

Future Oncol 8 961-87 08/01/2012

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Pravin T Kaumaya, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Education and Background

Office Location

Publications

Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics.

Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.

Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Pravin T Kaumaya, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Education and Background

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication